Last updated on February 2020

Study of Efficacy of CDZ173 in Patients With APDS/PASLI


Brief description of study

This study is designed to explore CDZ173, a selective PI3K inhibitor, in patients with genetically activated PI3K, i.e., patients with APDS/PASLI. The study consists of two parts. Part I is the open label part designed to establish the safety and pharmacokinetics of CDZ173 in the target population, as well as to select the optimal dose to be tested in part II. Part II is designed to assess efficacy and safety of CDZ173 in this population.

Detailed Study Description

This study is designed to explore CDZ173, a selective PI3K inhibitor, in patients with genetically activated PI3K, i.e., patients with APDS/PASLI (Activated phosphoinositide 3-kinase delta syndrome/ p110-activating mutation causing senescent T cells, lymphadenopathy and immunodeficiency)I.

The study consists of two parts. Part I is the open label part designed to establish the safety and pharmacokinetics of CDZ173 in the target population, as well as to select the optimal dose to be tested in part II.

Part II is designed to assess efficacy and safety of CDZ173 in this population.

Clinical Study Identifier: NCT02435173

Find a site near you

Start Over

Novartis Investigative Site

Dublin, Ireland
1.96miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.